CN113730445B - 一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用 - Google Patents
一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用 Download PDFInfo
- Publication number
- CN113730445B CN113730445B CN202110850183.6A CN202110850183A CN113730445B CN 113730445 B CN113730445 B CN 113730445B CN 202110850183 A CN202110850183 A CN 202110850183A CN 113730445 B CN113730445 B CN 113730445B
- Authority
- CN
- China
- Prior art keywords
- dietary fiber
- insoluble dietary
- ulcerative colitis
- acid
- precipitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 43
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 43
- 235000013325 dietary fiber Nutrition 0.000 title claims abstract description 40
- 241000512259 Ascophyllum nodosum Species 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title description 3
- 210000001072 colon Anatomy 0.000 claims abstract description 27
- 241000699670 Mus sp. Species 0.000 claims abstract description 22
- 230000000968 intestinal effect Effects 0.000 claims abstract description 18
- 230000036542 oxidative stress Effects 0.000 claims abstract description 5
- 238000004904 shortening Methods 0.000 claims abstract description 4
- 239000002244 precipitate Substances 0.000 claims description 19
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 150000002772 monosaccharides Chemical class 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 9
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 229940097043 glucuronic acid Drugs 0.000 claims description 9
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 229940118019 malondialdehyde Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 7
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 7
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 7
- 238000011033 desalting Methods 0.000 claims description 7
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- 102000004162 Claudin-1 Human genes 0.000 claims description 6
- 108090000600 Claudin-1 Proteins 0.000 claims description 6
- 102000003814 Interleukin-10 Human genes 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 6
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 6
- 230000000770 proinflammatory effect Effects 0.000 claims description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
- 108010057466 NF-kappa B Proteins 0.000 claims description 4
- 102000003945 NF-kappa B Human genes 0.000 claims description 4
- 102000000536 PPAR gamma Human genes 0.000 claims description 4
- 108010016731 PPAR gamma Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 230000009266 disease activity Effects 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- 102000003940 Occludin Human genes 0.000 claims description 3
- 108090000304 Occludin Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 230000000112 colonic effect Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims description 2
- 241000606125 Bacteroides Species 0.000 claims description 2
- 241000192125 Firmicutes Species 0.000 claims description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
- 241001261005 Verrucomicrobia Species 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 230000008984 colonic lesion Effects 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 229940005605 valeric acid Drugs 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 210000001578 tight junction Anatomy 0.000 claims 1
- 238000010172 mouse model Methods 0.000 abstract description 8
- 230000002757 inflammatory effect Effects 0.000 abstract description 5
- 239000002207 metabolite Substances 0.000 abstract description 4
- 102000002029 Claudin Human genes 0.000 abstract description 3
- 108050009302 Claudin Proteins 0.000 abstract description 3
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 235000013406 prebiotics Nutrition 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 239000000284 extract Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 239000013585 weight reducing agent Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 239000001913 cellulose Substances 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229920003045 dextran sodium sulfate Polymers 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 244000038651 primary producers Species 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003214 pyranose derivatives Chemical group 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用。本发明从海带残渣中提取不溶性膳食纤维,并构建了溃疡性结肠炎小鼠模型,首次验证了不溶性膳食纤维能够抑制由溃疡性结肠炎引起的小鼠体重降低、抑制结肠病变和缩短程度、改善结肠氧化应激水平、平衡体内炎症因子水平;上调肠道紧密连接蛋白的表达。所以,所述不溶性膳食纤维能够作为一种益生元成分靶向调节肠道菌群及其代谢产物,通过介导多个肠内代谢信号改善溃疡性结肠炎症状。
Description
技术领域
本发明属于食品保健领域,特别涉及一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用。
背景技术
炎症性肠病(Inflammatory bowel disease,IBD)包括克罗恩病(Crohn'sdisease,CD)和溃疡性结肠炎(Ulcerative Colitis,UC)两个亚型,是一组以肠道炎症和上皮损伤为病理特征的慢性复发性疾病,在西方国家发病率较高,在发展中国家发病率不断上升,且IBD患者常伴有焦虑、抑郁等精神疾病。
作为海洋中的初级生产者,海藻含有多种活性物质。其中海带膳食纤维因具有广泛的生物活性逐渐成为医药、食品领域的研究热点。作为大型海藻,海带几乎不含有木质素,使得纤维素具有更高的活性和可得性,使其逐渐成为基于饮食干预预防和缓解IBD保健食品的重要原料,但目前针对海洋源膳食纤维改善肠炎等胃肠道疾病的研究仍鲜有报道。
目前我国海带产量居世界第一位,但整体加工水平较低,诸多海带成分尚未得到有效的利用。海带废弃残渣中含有大量的膳食纤维,既造成了资源浪费,还导致环境污染,使海带产业始终无法发展壮大。因此,对海带的天然活性成分进行深入研究,有利于实现海带的高值化利用,发展海带产业。
发明内容
本发明的目的是为了提供了一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用。所述不溶性膳食纤维IDF提取自分离褐藻胶后的海带残渣,其来源丰富,安全性高,改善溃疡性结肠炎效果明显。
为实现上述目的,本发明采用的技术方案为:
一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用,所述不溶性膳食纤维的单糖组成包括葡萄糖和葡萄糖醛酸,二者的摩尔比为15-25:1。
优选的,所述不溶性膳食纤维的单糖组成为葡萄糖和葡萄糖醛酸,二者的摩尔比为21:1。
进一步的,所述不溶性膳食纤维的提取方法,包括以下步骤:
(1)向海带残渣中以1:20-40的料液比加入4-6% NaCl溶液,80-100℃加热6-8h进行脱钙处理,离心收集沉淀,纯水洗涤沉淀;
(2)向步骤(1)的沉淀中以1:20-40的料液比加入5mol/L NaOH溶液,pH调至碱性,80-100℃加热6-8h,离心收集沉淀;
(3)利用NaClO对步骤(2)中的沉淀进行脱色处理,然后再利用稀HCl进行除盐处理;
(4)除盐后的沉淀洗涤后干燥,研磨过200目筛,得到不溶性膳食纤维。
进一步的,所述步骤(1)中海带残渣为提取褐藻胶后的海带残渣。
进一步的,所述步骤(3)中NaClO的体积分数为9%,所述NaClO与沉淀的料液比为12:1,脱色处理时间为67min。
进一步的,所述步骤(3)中的沉淀经脱色处理后,所述不溶性膳食纤维的白度为39.53%±0.74%,得率为36.87%±0.69%。
进一步的,所述步骤(3)中稀HCl的浓度为0.5mol/L,所述稀HCl与脱色后的沉淀的料液比为1:1,除盐处理时间为1h。
进一步的,所述料液比的单位是mg/mL.
进一步的,所述不溶性膳食纤维改善溃疡性结肠炎的有效剂量为0.5g/kg-3.5g/kg。
进一步的,所述不溶性膳食纤维改善溃疡性结肠炎的最有效剂量为1.5g/kg。
进一步的,所述不溶性膳食纤维能够抑制溃疡性结肠炎小鼠体重下降并降低小鼠的疾病活动指数。
进一步的,所述不溶性膳食纤维能够抑制通过抑制溃疡性结肠炎小鼠结肠病变、缩短和肿胀程度来改善结肠的健康状况。
进一步的,所述不溶性膳食纤维能够降低溃疡性结肠炎小鼠结肠组织中的髓过氧化物酶MPO和丙二醛MDA含量以及增加超氧化物歧化酶酶SOD含量来改善小鼠结肠的氧化应激水平,并且提高小鼠体内短链脂肪酸的含量。
进一步的,所述短链脂肪酸包括乙酸、丙酸、丁酸、异丁酸、戊酸、异戊酸、己酸。
进一步的,所述不溶性膳食纤维能够下调溃疡性结肠炎小鼠结肠组织中促炎因子NF-κB、TNF-α的表达水平以及上调抑炎因子PPAR-γ、IL-10和肠道紧密连接蛋白ZO-1、Occludin、Claudin-1的表达水平。
进一步的,所述不溶性膳食纤维能够通过上调拟杆菌门和变形菌门的丰度以及抑制厚壁菌门和疣微菌门的丰度来恢复小鼠肠道菌群的多样性和丰度。
进一步的,所述不溶性膳食纤维能够增加科水平上Muribaculaceae占比,降低Erysipelotrichaceae和Akkermansiaceae占比。
与现有的技术相比,本发明的有益效果和优点在于:
本发明提取不溶性膳食纤维的原料是分离褐藻胶后的海带残渣,其来源丰富,使用安全。本发明提取的IDF属于天然膳食成分,主要成分为纤维素,包括葡萄糖醛酸和葡萄糖两种单糖,IDF结构紧实且具有一定的纤维网状结构,与陆生植物相比,海带几乎不含有木质素,因此IDF不仅增强纤维的亲水力、持油力、膨胀力等性能,进一步增强其生物活性和可得性,还提高了海带的高附加利用价值。
本发明对海带中IDF改善溃疡性结肠炎的作用和机制进行探究,重点研究了肠道菌群及其代谢产物介导的机制,其改善溃疡性结肠炎效果明显,不仅能够缓解结肠的组织病理学情况,还能抑制结肠内促炎因子等的表达,可以作为一种益生元成分靶向调节肠道菌群及其代谢产物,通过介导多个肠内代谢信号改善溃疡性结肠炎症状。所以IDF有发展成为治疗和改善溃疡性结肠炎的药物的巨大潜力。
附图说明
图1为IDF的单糖组成测定结果,其中A:10种单糖标准品高效液相色谱图;B:IDF的单糖组成高效液相色谱图。
图2为SEM对IDF的形貌表征,其中A:400×;B:1100×;C:1100×;D:1850×。
图3为IDF的红外光谱图。
图4为IDF的X-射线衍射图。
图5为溃疡性结肠炎模型小鼠的体重变化图和疾病活动指数(DAI)图。
图6为溃疡性结肠炎模型小鼠的结肠指标图。
图7为溃疡性结肠炎模型小鼠的结肠HE染色图。
图8为溃疡性结肠炎模型小鼠结肠的髓过氧化物酶(MPO)、丙二醛(MDA)和超氧化物歧化酶(SOD)含量图。
图9为溃疡性结肠炎模型小鼠结肠中炎症因子mRNA相对表达量图。
图10为溃疡性结肠炎模型小鼠结肠中炎症因子蛋白相对表达量图。
图11为溃疡性结肠炎模型小鼠结肠中肠道紧密连接蛋白mRNA相对表达量图。
图12为溃疡性结肠炎模型小鼠结肠中肠道紧密连接蛋白的蛋白相对表达量图。
图13为溃疡性结肠炎模型小鼠肠道菌群OUT分布图。
图14为溃疡性结肠炎模型小鼠肠道菌群科、门水平群落组成柱形图。
图15为溃疡性结肠炎模型小鼠粪便各短链脂肪酸(SCFAs)含量图。
具体实施方式
下面结合附图和具体实施方式对本发明的技术方案进一步的详细说明,但本发明要求保护的范围并不局限于实例表述的范围。
实施例1:不溶性膳食纤维的提取
本发明中不溶性膳食纤维的提取方法包括以下步骤:
(1)按照料液比1:30的比例往海带残渣中加入5% NaCl溶液,90℃加热7h进行脱钙处理;
(2)将步骤(1)中样品进行离心处理,收集沉淀加入适量纯水洗涤,再次收集沉淀;
(3)将步骤(2)中沉淀按照料液比1:30的比例加入5mol/L NaOH溶液,调节pH至碱性,90℃加热6h;
(4)将步骤(3)中样品离心,收集沉淀为不溶性膳食纤维(IDF);
(5)将步骤(4)中沉淀按照液料比为12:1加入体积分数为9%的NaClO,脱色时间67min,对IDF进行脱色处理;漂白后IDF的白度为39.53%±0.74%,得率为36.87%±0.69%;
(6)将步骤(5)中漂白后的IDF用200目纱布包住经超纯水水洗至中性并抽滤;
(7)向步骤(6)中经抽滤后IDF按照1:1的比例加入0.5mol/L稀HCl进行除盐处理1h;
(8)将步骤(7)中的除盐处理后的IDF用200目纱布包住经超纯水水洗至中性并抽滤,收集样品于50-60℃鼓风干燥;
(9)将步骤(8)中干燥好的IDF研磨并过200目筛,得到最终的IDF。
实施例2:海带不溶性膳食纤维(IDF)的基本结构鉴定
1、高效液相色谱对IDF的单糖组成测定
(1)准确称取实施例1制备的IDF 2mg,加入400μL 2mol/L三氟乙酸(TFA)溶液于安瓿瓶内,在105℃密封条件下降解6h。降解完成后,反复加甲醇除去多余三氟乙酸,将降解产物在干燥环境下保存。
(2)100μL蒸馏水充分溶解IDF降解产物及单糖标准品,加入100μL的0.3mol/LNaOH和120μL 0.5mol/L的PMP甲醇溶液,70℃水浴60min。冷却至室温后加入100μL的0.3mol/L HCl溶液进行中和反应,用二氯甲烷萃取3次除去未反应的PMP,0.22μm微孔滤膜过滤上清备用。
(3)利用HPLC测定IDF的单糖组成。色谱条件:色谱柱:Eclipse XDB-C18(5μm,4.6μm×25.0cm);流动相:乙腈:磷酸盐缓冲液(pH 6.7)=17:83(v/v);进样体积:10μL;柱温:35℃;检测器:紫外检测器(254nm);流速:1.0mL/min。
结果如图1所示,IDF的水解产物的HPLC洗脱曲线有两个特征峰,其单糖组成主要为葡萄糖,占样品的95.5%,葡萄糖醛酸占样品的4.5%,二者摩尔比为葡萄糖醛酸:葡萄糖=1:21。可见,IDF提取的纯度较高,主要由不溶性葡聚糖组成。
2、扫描电子显微镜对IDF的形貌表征
将实施例1制备的干燥且经研磨后的IDF样本放置在带有双面胶的载物台上,通过离子溅射镀膜在其表面镀金,置于SEM扫描观察,电压:5Kv,放大倍数:150×-1850×。
通过SEM对IDF的形貌进行表征,结果如图2所示。图2A和2B显示,IDF颗粒大小不一,表面粗糙不平,褶皱结构多且结构紧密;图2C和2D显示,IDF虽然结构紧实但仍具有一定的纤维网状结构:具有一定孔隙,呈现多层褶皱状的蓬松状态,可增加颗粒的比表面积,而比表面积可增强纤维的亲水力、持油力、膨胀力等性能,进一步增强其生物活性。
3、傅里叶红外光谱对IDF的结构分析
对IDF进行FT-IR定性分析。取干燥的实施例1制备的IDF和KBr(光谱级)100mg研磨并压成透明薄片,以空白KBr作为背景,扫描次数为20次,分辨率为4cm-1,扫描范围4000-400cm-1。
结果如图3所示,IDF具有纤维素分子的特征波段,在3148.21cm-1出现分子内伯羟基和仲羟基的O-H键的伸缩振动,在2921.18cm-1处出现纤维素结晶顺序下的C-H键的伸缩振动。此外,在1638.49cm-1为C=H的伸缩振动吸收峰,这与纤维素和水的强相互作用引起的吸水性有关。除了这些吸收峰之外,在光谱中还观察到其他特定的峰:1430.73cm-1和1428.50cm-1处出现CH2的弯曲振动和摆动振动;在1163.32cm-1处的吸收峰属于纤维素中D-葡萄糖之间β-1,4-糖苷键的C-O-C伸缩;位于1113.66cm-1、1060.36cm-1吸收峰分别属于C-O-C吡喃糖环骨架振动和C-O伸缩振动。结果表明海带IDF的主要成分为纤维素。
4、X-射线衍射对IDF的结晶相分析
利用XRD分析IDF的晶体结构和结晶度指数。X射线衍射仪参数条件:铜靶,入射线波长0.15418nm,Ni滤波片,管压40KV,管流40mA,扫描范围:5°-70°,扫描步长0.04度,扫描速度38.4秒/步;狭缝DS0.5°RS8 mm。随后利用Jade 6.0软件进行拟合分析。公式为:
式中:I200为2θ=22.64°附近的晶体峰强度,Iamp为2θ=14.38°附近波谷处测量的非晶体峰强度。
表1:IDF的峰型拟合相关参数
分析结果如表1和图4所示。由图4可看出,IDF在14.38、16.74、22.64和26.86出现了衍射峰,强度分别为2579、1931、5058、2661,这是纤维素I的特征。计算得知其CrI值为50.06%,比市售纤维素结晶程度(36.30%)偏高,说明其具有更有序的晶体结构。进一步计算半峰全宽度、晶面尺寸、间距(表1),得知晶系判别系数Z=18.74502>0,表明晶体结构以Iα型为主。相比于Iβ型,Iα型晶体结构由于其热不稳定性而更容易发生生化反应,其构效关系值得进一步研究。
实施例3
选取C57BL/6小鼠(雄性),7-8周龄,体重25-28g,饲养温度20-24℃,湿度40%-60%,期间自由饮水,摄食。实验分组如下:72只雄性C57BL/6小鼠适应性喂养7天后按照体重随机分成6组,每组12只,分别为正常组(NC)、模型组(MC)、阳性药组(PC)、低、中、高剂量IDF组(L-IDF、M-IDF、H-IDF)。适应性喂养结束进行受试物灌胃。每天上午9:00对各组小鼠进行受试物灌胃,持续7天。于第8天采用葡聚糖硫酸钠(DSS)建立溃疡性结肠炎模型,末次进食后,于第14天禁食不禁水过夜,隔天采取眼窝取血后脱颈椎方式处死小鼠,干预方案见表2。干预造模期间每日记录小鼠的摄食量、摄水量及体重,观察小鼠粪便状态及便血情况。
表2:IDF对溃疡性结肠炎小鼠模型的干预方案
实验结果如图5显示:海带IDF能有效抑制DSS所致肠炎小鼠体重的下降及疾病活动指数的升高,且以中剂量效果最好。
实施例4
实验分组与灌胃剂量同实施例3。实验结束后,切除小鼠的整个结肠观察溃疡程度并准确量取长度、重量。
实验结果如图6显示:与模型组相比,IDF干预能够增加小鼠结肠长度和重量,进而抑制肠炎小鼠结肠缩短和肿胀程度。
实施例5
实验分组与灌胃剂量同实施例3。实验结束后,取小鼠远端结肠约0.5cm转移至4%多聚甲醛固定液中。经过脱水、透明、浸蜡、包埋、切片与粘片、脱蜡、染色等步骤染色,使用切片机生成5μm横断面图,通过显微镜观察并记录组织学改变程度,评分标准如表3所示。
表3:结肠组织病理学评分标准
实验结果如图7显示:IDF使溃疡性结肠炎模型小鼠的结肠黏膜溃疡面积缩小,肠壁恢复,使得黏膜下层肿胀的程度减轻。
实施例6
实验分组与灌胃剂量同实施例3。实验结束后,准确称取结肠组织0.1g进行匀浆处理。2500~3000r/min,离心10min,取上清即10%匀浆上清液待测。根据BCA蛋白浓度测定试剂盒、丙二醛(MDA)、髓过氧化物酶(MPO)、超氧化物歧化酶(SOD)试剂盒说明书测定相关指标,分析肠道氧化应激水平。
实验结果如图8所示:IDF能够降低结肠MPO和MDA含量,上调SOD含量,进而改善小鼠肠道氧化应激水平。
实施例7
实验分组与灌胃剂量同实施例3。实验结束后,准确称取结肠组织0.1g按照Transzol的方法说明提取总RNA,按照One-Step gDNA Removal试剂盒将RNA反转录为cDNA,按照Top Green qPCR SuperMix(+Dye II)试剂盒进行实时荧光定量PCR检测炎症因子NF-κB、PPAR-γ、IL-10、TNF-α的mRNA表达量。
实验结果如图9显示:IDF抑制促炎因子NF-κB和TNF-α的mRNA表达,促进抑炎因子PPAR-γ和IL-10的表达,进而改善溃疡性结肠炎的炎性反应。
实施例8
实验分组与灌胃剂量同实施例3。实验结束后,分别取出0.1g结肠组织提取蛋白,蛋白免疫印迹法检测炎症因子NF-κB、PPAR-γ、IL-10、TNF-α的蛋白表达水平。
实验结果如图10显示:IDF下调促炎因子NF-κB和TNF-α的蛋白表达量,上调抑炎因子PPAR-γ和IL-10的蛋白表达量,M-IDF的效果相对更好一些。
实施例9
实验分组与灌胃剂量同实施例3。实验结束后,准确称取结肠组织0.1g进行匀浆处理。2500~3000r/min,离心10min,取上清即10%匀浆上清液待测。检测肠道紧密连接蛋白Occludin、ZO-1、Claudin-1mRNA表达量。
实验结果如图11显示:IDF上调Occludin、ZO-1和Claudin-1的mRNA表达量。
实施例10
实验分组与灌胃剂量同实施例3。准确称取结肠组织0.1g进行匀浆处理。2500~3000r/min,离心10min,取上清即10%匀浆上清液待测。检测肠道紧密连接蛋白Occludin、ZO-1、Claudin-1的蛋白表达水平。
实验结果如图12显示:IDF上调Occludin、ZO-1、Claudin-1的蛋白表达水平。
实施例11
实验分组与灌胃剂量同实施例3。实验结束前一天,将小鼠分别放入干净无菌的鼠笼中,收集小鼠粪便,。通过DNA抽提、设计合成引物接头、PCR扩增与产物纯化、PCR产物定量与均一化、构建PE文库等流程进行16S rRNA V3-V4区扩增,测序平台为Illumina。按照97%相似性对非重复序列进行OTU聚类,采用RDP classifier贝叶斯算法对97%相似水平的OTU代表序列进行物种组成分析。
实验结果如图13和14显示:Venn图结果表明,MC组、IDF组分别与NC组共有378、402个OUT。门水平柱形图显示IDF增加Bacteroidota的丰度至54.1%,下调Firmicutes的丰度至29.0%,并下调Firmicutes/Bacteroidota比值。科水平柱形图显示IDF增加Muribaculaceae占比,降低Erysipelotrichaceae和Akkermansiaceae占比。
实施例12
实验分组与灌胃剂量同实施例3。实验结束前一天,将小鼠分别放入干净无菌的鼠笼中,收集小鼠粪便。首先精确称取一定质量的样本,于低温环境下加入提取液进行代谢物萃取处理。配制不同浓度的标准溶液,在同一条件下对标准溶液和待测样品进行GC-MS上机检测,根据标准曲线计算出检测样品的目标物质的浓度,最终换算得到样品浓度。
实验结果如图15显示:IDF干预后,总SCFAs及乙酸、丙酸、丁酸、异丁酸等各类短链脂肪酸水平都得到上调。
以上实施例仅用以说明本发明的技术方案,而非对其进行限制;尽管参照前述实施例对本发明进行了详细的说明,对于本领域的普通技术人员来说,依然可以对前述实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或替换,并不使相应技术方案的本质脱离本发明所要求保护的技术方案的精神和范围。
Claims (1)
1.一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用,其特征在于:所述不溶性膳食纤维中单糖组成包括葡萄糖和葡萄糖醛酸,二者的摩尔比为21:1;所述不溶性膳食纤维改善溃疡性结肠炎的最有效剂量为1.5g/kg;
(1)向海带残渣中以1:30的料液比加入5% NaCl溶液,90℃加热7h进行脱钙处理,离心收集沉淀,纯水洗涤沉淀;
(2)向步骤(1)的沉淀中以1:30的料液比加入5mol/L NaOH溶液,pH调至碱性,90℃加热6 h,离心收集沉淀;
(3)利用NaClO对步骤(2)中的沉淀进行脱色处理,然后再利用稀HCl进行除盐处理;所述NaClO的体积分数为9%,所述NaClO与沉淀的料液比为12:1,脱色处理时间为67min;
所述稀HCl的浓度为0.5mol/L,所述稀HCl与脱色后的沉淀的料液比为1:1,除盐处理时间为1h;
(4)除盐后的沉淀洗涤后干燥,研磨过200目筛,得到不溶性膳食纤维;
所述不溶性膳食纤维能够下调溃疡性结肠炎小鼠结肠组织中促炎因子NF-κB、TNF-α的表达水平以及上调抑炎因子PPAR-γ、IL-10和肠道紧密连接蛋白ZO-1、Occludin、Claudin-1的表达水平;
所述不溶性膳食纤维能够抑制由溃疡性结肠炎引起的小鼠体重下降,并降低小鼠的疾病活动指数;所述不溶性膳食纤维能够抑制通过抑制溃疡性结肠炎小鼠结肠病变、缩短和肿胀程度来改善结肠的健康状况;所述不溶性膳食纤维能够降低溃疡性结肠炎小鼠结肠组织中的髓过氧化物酶MPO和丙二醛MDA含量以及增加超氧化物歧化酶酶SOD含量来改善小鼠结肠的氧化应激水平,并且提高小鼠体内短链脂肪酸的含量;所述短链脂肪酸为乙酸、丙酸、丁酸、异丁酸、戊酸、异戊酸、己酸;所述不溶性膳食纤维能够通过上调拟杆菌门和变形菌门的丰度以及抑制厚壁菌门和疣微菌门的丰度来恢复小鼠肠道菌群的多样性和丰度。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110850183.6A CN113730445B (zh) | 2021-07-27 | 2021-07-27 | 一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110850183.6A CN113730445B (zh) | 2021-07-27 | 2021-07-27 | 一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113730445A CN113730445A (zh) | 2021-12-03 |
CN113730445B true CN113730445B (zh) | 2023-07-18 |
Family
ID=78729188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110850183.6A Active CN113730445B (zh) | 2021-07-27 | 2021-07-27 | 一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113730445B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018214855A1 (zh) * | 2017-05-23 | 2018-11-29 | 北京瑞千景科技发展有限公司 | 改善营养代谢肠功能及微生态的抗炎组合物和食品及应用 |
CN114668775A (zh) * | 2022-02-28 | 2022-06-28 | 中国药科大学 | 纤维素衍生物在制备治疗溃疡性结肠炎药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110787191A (zh) * | 2019-11-25 | 2020-02-14 | 自然资源部第一海洋研究所 | 一种海带中可溶性膳食纤维在制备降脂减肥的药物和功能性食品中的应用 |
CN110787192B (zh) * | 2019-11-25 | 2021-10-26 | 自然资源部第一海洋研究所 | 一种海带中可溶性膳食纤维在制备降糖的药物和功能性食品中的应用 |
CN111671765B (zh) * | 2020-05-29 | 2023-08-22 | 中国科学院海洋研究所 | 一种褐藻膳食纤维在制备治疗或预防代谢综合症的药品、食品和/或保健品中的应用 |
-
2021
- 2021-07-27 CN CN202110850183.6A patent/CN113730445B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018214855A1 (zh) * | 2017-05-23 | 2018-11-29 | 北京瑞千景科技发展有限公司 | 改善营养代谢肠功能及微生态的抗炎组合物和食品及应用 |
EP3632222A1 (en) * | 2017-05-23 | 2020-04-08 | Beijing Ruiqianjing Science And Technology Development Co. Ltd. | Anti-inflammatory composition for improving intestinal nutritional metabolism functions and intestinal microecology, food containing same, and application thereof |
CN114668775A (zh) * | 2022-02-28 | 2022-06-28 | 中国药科大学 | 纤维素衍生物在制备治疗溃疡性结肠炎药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113730445A (zh) | 2021-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0356484B1 (en) | Process for preparation of aloe products | |
CN112921059B (zh) | 蕉芋rs3抗性淀粉的制备方法及在功能食品和抗帕金森药物中的应用 | |
WO1995007084A1 (de) | Blockierung der anlagerung von keimen an menschliche zellen | |
CN113730444A (zh) | 一种海带中可溶性膳食纤维在制备用于改善溃疡性结肠炎的药物和功能性食品中的应用 | |
Zhang et al. | Physicochemical characterization, adsorption function and prebiotic effect of chitin-glucan complex from mushroom Coprinus comatus | |
CH653349A5 (de) | Polysaccharide, ihre herstellung und diese enthaltende therapeutische zusammensetzungen. | |
CN113730445B (zh) | 一种海带中不溶性膳食纤维在制备用于改善溃疡性结肠炎的药物中的应用 | |
CN117815262A (zh) | 一种苣荬菜多糖类提取物在防治溃疡性结肠炎中的应用 | |
CN112691115A (zh) | 预防/治疗胃肠粘膜和肝脏损伤的阿拉伯木聚糖及复合物 | |
CN106749733B (zh) | 一种泡叶藻硫酸酯化多糖及其制备方法、应用 | |
WO2023036203A1 (zh) | Cs-4发酵菌丝体杂聚多糖及其制备方法与用途 | |
CN112961261B (zh) | 阳春砂根茎多糖及其制备方法和抗氧化的应用 | |
CN1931181A (zh) | 银耳杂多糖或其提取物的新用途 | |
CN108079001B (zh) | 木聚糖酯化产物在制备预防或治疗炎症性疾病及癌症药物中的应用 | |
Zhang et al. | A polysaccharide from Allium tenuissimum L. flowers relieves ulcerative colitis by regulating the inflammatory signaling pathway and gut microbiota | |
WO2009054662A2 (en) | Wound-healing agent containing momordicae semen extract | |
CN114617915A (zh) | 一种桢楠水溶性提取物的制备方法及其应用 | |
CN113648332A (zh) | 一种海带中不溶性膳食纤维在制备用于改善便秘的药物和功能性食品中的应用 | |
CN113893268B (zh) | 金针菇子实体膳食纤维、提取方法及其在制备减重药物或治疗肥胖症药物中的应用 | |
CN116333187A (zh) | 一种香蕉果肉中百分百甲酯化果胶的制备与应用 | |
CN1560088A (zh) | 一种硒化葡甘聚糖的制备方法 | |
CN115043956B (zh) | 一种接骨木多糖及其多糖组合物与应用 | |
CN115232221B (zh) | 具有防治肺部感染的薜荔多糖及其制备方法与应用 | |
CN114558026B (zh) | 半枝莲多糖在制备治疗炎症性肠病的药物中的应用 | |
CN103381205B (zh) | 蜈蚣三七提取物在制备肠粘连药物中的应用及其药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |